Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (101-110 of 253) with videos related to

Pageof 26
Sort By:
Endocrine Journal|July 28, 2015
A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the diseaseMariyo Rokutan, Daisuke Yabe, Izumi Komoto, et al.
Nutrients|February 27, 2026
D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese MiceYermek Rakhat, Seiya Banno, Dauren Zhantleu, et al.
Journal of Diabetes Investigation|April 8, 2026
Life-threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry-based cross-sectional studyDaisuke Chujo, Akihisa Imagawa, Junnosuke Miura, et al.
Diabetes, Obesity & Metabolism|October 8, 2021
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trialsYuichiro Yamada, Daisuke Yabe, Christin Løth Hertz, et al.
Diabetes Research and Clinical Practice|September 16, 2008
A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestionDaisuke Yabe, Akira Kuroe, Michihiro Ohya, et al.
Diabetology International|July 3, 2025
Longitudinal monitoring of urinary C-peptide levels following discontinuation of sacubitril/valsartan in a type 2 diabetes patient: a case report and literature reviewKeiichiro Kondo, Hiroto Minamino, Takaaki Murakami, et al.
The Journal of Biological Chemistry|October 18, 2003
Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniolNavdar Sever, Bao-Liang Song, Daisuke Yabe, et al.
Journal of Diabetes Investigation|February 3, 2022
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trialsDaisuke Yabe, Srikanth Deenadayalan, Hiroshi Horio, et al.
Lancet (London, England)|March 1, 2026
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialJulio Rosenstock, Daisuke Yabe, David Cox, et al.
Diabetology International|February 26, 2019
Correction to: Japanese Clinical Practice Guideline for Diabetes 2016Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, et al.
Pageof 26

Showing results (101-110 of 253) with videos related to

Sort By:
Pageof 26
Endocrine Journal|July 28, 2015
A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the diseaseMariyo Rokutan, Daisuke Yabe, Izumi Komoto, et al.
Nutrients|February 27, 2026
D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese MiceYermek Rakhat, Seiya Banno, Dauren Zhantleu, et al.
Journal of Diabetes Investigation|April 8, 2026
Life-threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry-based cross-sectional studyDaisuke Chujo, Akihisa Imagawa, Junnosuke Miura, et al.
Diabetes, Obesity & Metabolism|October 8, 2021
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trialsYuichiro Yamada, Daisuke Yabe, Christin Løth Hertz, et al.
Diabetes Research and Clinical Practice|September 16, 2008
A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestionDaisuke Yabe, Akira Kuroe, Michihiro Ohya, et al.
Diabetology International|July 3, 2025
Longitudinal monitoring of urinary C-peptide levels following discontinuation of sacubitril/valsartan in a type 2 diabetes patient: a case report and literature reviewKeiichiro Kondo, Hiroto Minamino, Takaaki Murakami, et al.
The Journal of Biological Chemistry|October 18, 2003
Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniolNavdar Sever, Bao-Liang Song, Daisuke Yabe, et al.
Journal of Diabetes Investigation|February 3, 2022
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trialsDaisuke Yabe, Srikanth Deenadayalan, Hiroshi Horio, et al.
Lancet (London, England)|March 1, 2026
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialJulio Rosenstock, Daisuke Yabe, David Cox, et al.
Diabetology International|February 26, 2019
Correction to: Japanese Clinical Practice Guideline for Diabetes 2016Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, et al.
Pageof 26